Physician
Mandal, Rakesh
Mandal, Rakesh was paid $548K by Medicaid between Jul 2018 and Oct 2024, across 126 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 7.2% of everything it billed.
33Billing provider infoMANDAL, RAKESH
MADISON, WI 53792
MADISON, WI 53792
33aNPI1629336524assigned 04/27/2012
33bProvider typeClinical Pathology/Laboratory Medicine Physician
28Total paid$548K
24GClaims76,556
24DCodes billed126
24AFirst – last monthJul 2018 – Oct 2024
Compared with peers
Next to other Clinical Pathology/Laboratory Medicine Physician providers in Wisconsin
Rank by total paid#2 of 5
Median peer was paid$9K
This provider vs. median58×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 144 | $4K | |
| 2019 | 147 | $5K | |
| 2020 | 190 | $4K | |
| 2021 | 306 | $8K | |
| 2022 | 3,956 | $37K | |
| 2023 | 49,750 | $386K | |
| 2024incomplete | 22,063 | $105K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 7.2% | 7,904 | 6,707 | $39K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 6.9% | 151 | 148 | $38K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6.2% | 617 | 522 | $34K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 5.3% | 923 | 822 | $29K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.2% | 10,257 | 7,986 | $29K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 5.0% | 1,369 | 1,357 | $27K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.0% | 1,369 | 1,357 | $27K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.2% | 560 | 551 | $23K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3.7% | 488 | 474 | $20K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.5% | 248 | 245 | $19K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.7% | 1,906 | 1,875 | $15K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.0% | 471 | 439 | $11K |
114 more codes
| 87086 | Culture, bacterial; quantitative colony count, urine | 2.0% | 2,292 | $11K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.8% | 2,392 | $10K |
| 83735 | 1.8% | 2,783 | $10K | |
| 82803 | 1.7% | 746 | $9K | |
| 87510 | 1.4% | 601 | $8K | |
| 87480 | 1.4% | 600 | $8K | |
| 87081 | 1.2% | 2,415 | $7K | |
| 83605 | 1.2% | 1,218 | $7K | |
| 87040 | 1.2% | 708 | $7K | |
| 88307 | 1.2% | 89 | $6K | |
| 87660 | 1.1% | 750 | $6K | |
| 82962 | 1.0% | 2,736 | $6K | |
| 80061 | Lipid panel | <1% | 1,499 | $5K |
| 84484 | <1% | 959 | $5K | |
| 87641 | <1% | 248 | $5K | |
| 82330 | <1% | 621 | $5K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 350 | $5K |
| 88342 | <1% | 232 | $4K | |
| 83880 | <1% | 368 | $4K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 204 | $4K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 448 | $4K |
| 87186 | <1% | 705 | $4K | |
| 85730 | <1% | 829 | $4K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 138 | $3K |
| 86780 | <1% | 431 | $3K | |
| 83690 | <1% | 936 | $3K | |
| 86803 | <1% | 406 | $3K | |
| 84100 | <1% | 1,313 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 968 | $3K |
| 86850 | <1% | 929 | $3K | |
| 80069 | <1% | 649 | $3K | |
| 81025 | <1% | 1,019 | $3K | |
| 82607 | <1% | 465 | $3K | |
| 85610 | <1% | 1,285 | $3K | |
| 88341 | <1% | 46 | $2K | |
| 81001 | <1% | 1,631 | $2K | |
| 88189 | <1% | 42 | $2K | |
| 86901 | <1% | 1,021 | $2K | |
| 84439 | <1% | 492 | $2K | |
| 86140 | <1% | 888 | $2K | |
| 80202 | <1% | 291 | $2K | |
| 85060 | <1% | 173 | $2K | |
| 86003 | <1% | 52 | $2K | |
| 82728 | <1% | 468 | $2K | |
| 84466 | <1% | 458 | $2K | |
| 86900 | <1% | 1,017 | $2K | |
| 82784 | <1% | 191 | $1K | |
| 82746 | <1% | 262 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 90 | $1K |
| 83540 | <1% | 458 | $1K | |
| 87070 | <1% | 408 | $1K | |
| 85027 | <1% | 455 | $1K | |
| 87147 | <1% | 756 | $1K | |
| 87088 | <1% | 266 | $1K | |
| 81003 | <1% | 1,088 | $1K | |
| 85384 | <1% | 346 | $1K | |
| 82570 | <1% | 498 | $1K | |
| 86038 | <1% | 154 | $1K | |
| 87340 | <1% | 180 | $1K | |
| 83970 | <1% | 76 | $1K | |
| 84702 | <1% | 229 | $1K | |
| 85379 | <1% | 265 | $991.94 | |
| 82550 | <1% | 345 | $989.20 | |
| 82805 | <1% | 33 | $951.17 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 108 | $950.40 |
| 84703 | <1% | 245 | $831.11 | |
| 80047 | <1% | 177 | $820.76 | |
| 83615 | <1% | 298 | $811.81 | |
| 83516 | <1% | 117 | $772.67 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 96 | $745.75 |
| 85014 | <1% | 511 | $679.76 | |
| 85652 | <1% | 517 | $636.91 | |
| 86480 | <1% | 28 | $597.36 | |
| 82043 | <1% | 275 | $506.56 | |
| 87205 | <1% | 258 | $497.26 | |
| 82565 | <1% | 213 | $476.10 | |
| 84478 | <1% | 221 | $468.93 | |
| 87075 | <1% | 65 | $454.05 | |
| 82247 | <1% | 187 | $450.79 | |
| 84550 | <1% | 200 | $405.61 | |
| 84145 | <1% | 20 | $400.05 | |
| 82785 | <1% | 77 | $366.34 | |
| 80076 | <1% | 99 | $366.32 | |
| 83655 | <1% | 64 | $349.92 | |
| 82248 | <1% | 178 | $344.92 | |
| 85576 | <1% | 16 | $316.71 | |
| 86920 | <1% | 59 | $310.20 | |
| 87493 | <1% | 13 | $297.83 | |
| 85045 | <1% | 228 | $290.39 | |
| 85018 | <1% | 198 | $256.36 | |
| 86762 | <1% | 61 | $255.91 | |
| 86706 | <1% | 40 | $242.73 | |
| 84156 | <1% | 205 | $228.88 | |
| 88304 | <1% | 13 | $226.24 | |
| 84481 | <1% | 43 | $215.06 | |
| 87210 | <1% | 56 | $211.50 | |
| 82140 | <1% | 28 | $163.20 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 15 | $157.96 |
| 85347 | <1% | 59 | $140.95 | |
| 84403 | <1% | 13 | $132.72 | |
| 86880 | <1% | 43 | $129.05 | |
| 80306 | <1% | 19 | $113.81 | |
| 86403 | <1% | 30 | $103.80 | |
| 86431 | <1% | 29 | $87.06 | |
| 84480 | <1% | 14 | $66.92 | |
| 80177 | <1% | 15 | $62.52 | |
| 83020 | <1% | 13 | $56.03 | |
| 84295 | <1% | 14 | $44.27 | |
| 84300 | <1% | 18 | $38.16 | |
| 82009 | <1% | 27 | $38.00 | |
| 82950 | <1% | 17 | $31.49 | |
| 89050 | <1% | 14 | $24.51 | |
| 84157 | <1% | 16 | $21.00 | |
| 81015 | <1% | 12 | $14.42 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.